These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32981222)

  • 1. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.
    Megna M; Fabbrocini G; Ferrillo M; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14351. PubMed ID: 32981222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of treatment strategies for erythrodermic psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    J Dermatolog Treat; 2021 Feb; 32(1):49-55. PubMed ID: 31682547
    [No Abstract]   [Full Text] [Related]  

  • 3. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of erythrodermic psoriasis with biologics: A systematic review.
    Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
    J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G; Errichetti E
    BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
    Puig L; Lebwohl M; Bachelez H; Sobell J; Jacobson AA
    J Am Acad Dermatol; 2020 Feb; 82(2):352-359. PubMed ID: 31175909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
    Bagel J; Lebwohl M; Israel RJ; Jacobson A
    J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixekizumab as treatment of erythrodermic psoriasis.
    Trovato E; Orsini C; Russo F; Cortonesi G; Rubegni P
    Dermatol Ther; 2021 Mar; 34(2):e14868. PubMed ID: 33571383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of brodalumab for the treatment of psoriasis.
    Iznardo H; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of erythrodermic psoriasis successfully treated with guselkumab.
    Megna M; Ruggiero A; Camela E; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Mar; 33(2):e13238. PubMed ID: 31997488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab.
    Megna M; Ruggiero A; Salsano A; Lauletta G; Portarapillo A; Torta G; Martora F; Potestio L
    Clin Cosmet Investig Dermatol; 2023; 16():3503-3507. PubMed ID: 38077922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
    Gottlieb A; Lebwohl M; Liu C; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2020 Jun; 21(3):421-430. PubMed ID: 32207067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.